King was born in 1950.[1] He moved from Taiwan to the United States with his family when he was 10 years old. He learned English from an elementary school teacher in Richmond, Virginia after living in the U.S. and was one of only two Asians in his elementary and high school classes. His father suffered from diabetes.[4]
King has been affiliated with Joslin and Harvard since 1981.[3] He was elected to The American Society for Clinical Investigation in 1986.[8] He has published over 350 scientific papers, which have been cited nearly 100 thousand times.[9] These articles mostly correspond to topics in Internal Medicine, Endocrinology and Diabetes Mellitus. His current research aims at finding protective biochemical factors acting to prevent complications in a large, special group of medalisttype 1 diabetic patients who have remained relatively healthy even after 50 or more years suffering the disease.[10][11] King also leads a national effort to improve care for diabetes in Asian Americans, who develop diabetes at low body weight.[12] King is the founder of Joslin's Asian American Diabetes Initiative,[13] which runs Asian Diabetes Clinic, a provider of exceptional patient care, and culture tailored education materials.[12] Since 2011, he Co-chair AANHPI Diabetes Coalition, a large national advocacy group aiming to improve diabetes prevention and management in Asian Americans.[14] In 2018, he was elected a Fellow of the American Association for the Advancement of Science in the biological sciences section.[15]
Research
King’s research focuses on finding the causes of diabetic complications.[16][17] He founded the Medalist Study to investigate new treatments for diabetic complications, and to understand the reasons for the high rate of diabetes in Asian Americans.[18] His laboratory studies the molecular mechanisms that cause vascular complications caused by hyperglycemia and insulin resistance.[19] He discovered that VEGF is an important causal factor in the severe form of diabetic eye disease.[20] King´s laboratory has played a pioneering role in the characterization of endogenous protective factors originating in tissues which can neutralize the toxic effect of hyperglycemia and insulin resistance.[21][22]
Awards
1986 - Elected Fellow of the American Society of Clinical Investigation[23]
1988 - Lilly Clinical Scholar and Visiting Professor[24]
1989-1990 - Cogan Award, Association for Research in Vision and Ophthalmology[6]
↑ He, Zhiheng; King, George L. (2004). "Microvascular complications of diabetes". Endocrinology and Metabolism Clinics of North America. 33 (1): 215–238, xi–xii. doi:10.1016/j.ecl.2003.12.003. ISSN0889-8529. PMID15053904.
↑ King, George L.; Loeken, Mary R. (2004). "Hyperglycemia-induced oxidative stress in diabetic complications". Histochemistry and Cell Biology. 122 (4): 333–338. doi:10.1007/s00418-004-0678-9. ISSN0948-6143. PMID15257460.
↑ Keenan, Hillary A.; Costacou, Tina; Sun, Jennifer K.; Doria, Alessandro; Cavellerano, Jerry; Coney, Joseph; Orchard, Trevor J.; Aiello, Lloyd Paul; King, George L. (2007). "Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study". Diabetes Care. 30 (8): 1995–1997. doi:10.2337/dc06-2222. ISSN1935-5548. PMID17507696.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
